作为社区痴呆症生物标志物的血GFAP和NEFL的临床用处
Hai-Yun Li1, Yue-Ting Deng1, Yu Guo1
1Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai, China.
Journal of neurochemistry
|August 28, 2025
概括
血纤维酸性蛋白 (GFAP) 和神经纤维光链 (NEFL) 对阿尔茨海默氏症和血管痴呆症具有很强的预测价值. 纳入人口和遗传因素可以提高社区环境中痴呆症预测的准确性.
科学领域:
- 神经学
- 生物标志物
- 老年学
背景情况:
- 血纤维酸蛋白 (GFAP) 和神经丝轻链 (NEFL) 是神经退行性疾病的新兴生物标志物.
- 它们在基于社区的痴呆症预测中的实用性仍未得到充分研究.
研究的目的:
- 在大型社区队列中评估血GFAP和NEFL对痴呆症的预测性能.
- 确定影响这些生物标志物的因素,并评估它们对预测准确性的影响.
主要方法:
- 对36153名英国生物库参与者 (年龄在39-70岁) 的分析,随访时间中位数为10.53年.
- 用于预测性能的接收器操作特征 (ROC) 分析.
- 线性回归以确定影响因素 (人口统计学,生活方式,并发症,遗传学).
主要成果:
- 在阿尔茨海默病 (AD) 和血管痴呆症 (VaD) 中,GFAP和NEFL具有显著的预测价值 (AUC=0. 76- 0. 83).
- 生物标志物水平与心室体积和反应时间较慢相关.
- 在纳入人口,环境和遗传因素 (例如,APOE rs429358) 时,预测准确度大大提高 (AUC=0.86-0.89).
结论:
- 血GFAP和NEFL是一般人群中痴呆症的有价值预测因素.
- 了解影响因素对于改进痴呆风险评估至关重要.
- 这些发现支持建立加强社区查的临床参考范围.
相关概念视频
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21